



Global Product Development

19 August 2021

Marion Gruber, Ph.D.
Director
Office of Vaccines Research and Review
Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Avenue
WO71, G112
Silver Spring, MD 20993-0002

THIS DOCUMENT CONTAINS
CONFIDENTIAL AND/OR TRADE SECRET
INFORMATION THAT IS DISCLOSED ONLY
IN CONNECTION WITH THE LICENSING
AND/OR REGISTRATION OF PRODUCTS FOR
PFIZER INC OR ITS AFFILIATED
COMPANIES. THIS DOCUMENT SHOULD
NOT BE DISCLOSED OR USED, IN WHOLE OR
IN PART, FOR ANY OTHER PURPOSE
WITHOUT THE PRIOR WRITTEN CONSENT
OF PFIZER INC.

Re: BLA 125742

COVID-19 mRNA Vaccine (BNT162/PF-07302048)

**Response to FDA 17 August 2021 Information Request Regarding Drug
Substance (b) (4) for (b) (4) and Drug Product (b) (4)
(b) (4) at Kalamazoo and Puurs**

Dear Dr. Gruber,

Reference is made to the Biologics License Application (BLA) submitted 18 May 2021 for the COVID-19 mRNA Vaccine (BNT162/PF-07302048) developed by BioNTech and Pfizer under BB-IND 19736 for the prevention of COVID-19 caused by SARS-CoV-2 in individuals ≥ 16 years of age.

The purpose of this submission is to respond to CBER's 17 August 2021 Information Request, received via email regarding drug substance (b) (4) and drug product (b) (4). The [Response to FDA 17 August 2021 Information Request](#) is provided in Module 1.11.1.

Should you have any questions regarding this submission, or require additional information, please contact me via phone at 215-280-5503; via facsimile at 845-474-3500; or via e-mail at elisa.harkinstull@pfizer.com.

Sincerely,

Elisa Harkins
Global Regulatory Lead
Global Regulatory Affairs – Vaccines

CC: Ramachandra S. Naik, Ph.D.

CC: Michael Smith, Ph.D.

CC: Laura Gottschalk, Ph.D.